Asia

The Chinese biotech will work with Pfizer on three in vivo CAR T therapies for autoimmune indications.
Speaking at the Jefferies conference in London, Pfizer CEO Albert Bourla warned of China’s rise and spoke to how companies like his can compete by leveraging AI-discovered savings.
How India and other emerging hubs for drug development can be key to reshaping medical costs globally.
October marked the first time this year there was an increase in both the number of biotech and pharma companies trimming their workforces and the number of affected employees when compared to 2025. Still, it’s highly unlikely 2026 layoffs will come close to matching the downsizing seen last year.
Neither Chongqing Qiancan Technology nor Tianjin Healthcare Medical Technology provided the records requested by the FDA, leading the agency to issue import alerts and warning letters.
Novartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about the risk of a rare eye condition that can lead to vision loss; and the agency is set to decide on no fewer than 11 therapies this month, including closely watched applications from Summit Therapeutics, Vertex and Capricor Therapeutics.
To grow into a biopharma juggernaut, China aims to become the leading source of innovative medicines on the global markets—a goal that experts say the country is on track to hit.
Policy uncertainty is hampering the growth of U.S. biotech as China rises thanks to carefully planned investment in the industry, experts said during a BioSpace webinar.
The seven proposals in the Bio Advance plan include easing clinical trial starts, boosting manufacturing and establishing a new White House office to coordinate the government’s biotech policy.
Evommune is commiting $30 million upfront for Hinova Pharmaceuticals’ oral molecular glue degrader—a low-cost bet with a high probability of success, according to analysts, after clinical failures roiled the biotech’s internal pipeline earlier this year.
PRESS RELEASES